.jpeg)
2026-08-06 07:11:28
Phase 3 FIGHT-302 data presented at the 2026 ASCO Annual Meeting demonstrate that pemigatinib (Pemazyre) as first-line monotherapy significantly prolongs progression-free survival versus gemcitabine plus cisplatin in patients with FGFR2-rearranged unresectable cholangiocarcinoma, establishing a new precision-targeted standard for this molecularly defined population.
2026-08-06 06:54:38
Selpercatinib (Retevmo) is the first approved highly selective RET kinase inhibitor, dosed twice daily at 120 mg or 160 mg based on body weight, indicated for RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and other RET-altered malignancies.
2026-08-06 06:49:15
Mitotane is the cornerstone drug for adrenocortical carcinoma treatment, yet its side-effect profile extends well beyond common gastrointestinal discomfort to include adrenal insufficiency, neurological effects, and hepatic changes, necessitating systematic monitoring and proactive clinical management.
2026-08-05 03:49:14
Axitinib is a highly selective oral VEGFR tyrosine kinase inhibitor approved for advanced renal cell carcinoma (RCC) as first-line combination therapy and second-line monotherapy. This article reviews its indications, composition, mechanism of action, critical pre-treatment warnings, and drug interactions to support safe clinical use.
2026-08-05 03:34:24
Capmatinib (Tabrecta) is the first highly selective MET inhibitor approved for MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). This article covers the purchasing channels, reliability assessment, efficacy data, version differences, and safety monitoring tips for the Laos generic version, helping patients make informed treatment decisions.
2026-08-04 03:43:45
Eltrombopag olamine is a key oral thrombopoietin receptor agonist (TPO-RA) used in the treatment of immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). This guide details the correct administration timing requirements, alternative options when the originator product is unavailable, switching precautions, and safety monitoring to support standardized patient care.
2026-08-04 03:22:38
Osimertinib is a cornerstone targeted therapy for EGFR mutation-positive non-small cell lung cancer (NSCLC). This comprehensive guide covers its composition, mechanism of action, critical food interactions (three fruits and vegetables to avoid), pre-treatment assessments, and drug interaction management to ensure safe and effective use.
2026-07-31 05:29:27
Tivozanib (brand name FOTIVDA) is an oral, highly selective VEGFR tyrosine kinase inhibitor primarily indicated for patients with advanced renal cell carcinoma who have progressed after multiple prior systemic therapies, representing a key advancement in precision-targeted kidney cancer treatment.
2026-07-30 06:32:34
A systematic review of the highly selective MET inhibitor capmatinib in MET exon 14 skipping mutation non-small cell lung cancer, covering efficacy data, horizontal comparison with tepotinib, first-line and later-line monotherapy strategies, and emerging combination therapy directions.
2026-07-30 04:19:01
A comprehensive analysis of the highly selective RET inhibitor pralsetinib, covering discontinuation criteria, comparative efficacy with selpercatinib, and first-line and later-line treatment strategies for RET fusion-positive solid tumors.
2026-07-30 03:05:05
A comprehensive overview of dabrafenib's approved indications, monotherapy versus combination with trametinib, and comparative analysis with vemurafenib and encorafenib for BRAF V600-mutant solid tumors.
2026-07-23 05:37:53
Cabozantinib (Cabozantinib) capsules are a multi-target tyrosine kinase inhibitor approved for progressive, metastatic medullary thyroid cancer (MTC), inhibiting RET, MET, and VEGFR signaling pathways to control tumor progression.
